Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 4/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | MME | P08473 | 1/20 | 0.32 |
| ▸ | MGAM | O43451 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 2/20 | 0.32 |
| ▸ | SI | P14410 | 2/20 | 0.32 |
| ▸ | MGAM2 | Q2M2H8 | 2/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27575981 | 0.91 | ZDHHC7 (0.47) | ZDHHC7SMN1; SMN2CA1CA2CA14 | |
| SCHEMBL29038034 | 0.87 | ZDHHC7 (0.48) | ZDHHC7SMN1; SMN2CA14CA12MME | |
| SCHEMBL6683720 | 0.87 | ZDHHC7 (0.48) | ZDHHC7SMN1; SMN2CA1CA2CA14 | |
| SCHEMBL936362 | 0.87 | ZDHHC7 (0.48) | ZDHHC7SMN1; SMN2CA14CA12MME | |
| SCHEMBL106430 | 0.85 | ZDHHC7 (0.47) | ZDHHC7SMN1; SMN2CA1CA2CA14 | |
| SCHEMBL9352213 | 0.85 | ZDHHC7 (0.43) | ZDHHC7SMN1; SMN2CA1CA2CA14 | |
| SCHEMBL22162842 | 0.84 | ZDHHC7 (0.46) | ZDHHC7SMN1; SMN2CA1CA2CA14 | |
| SCHEMBL22162843 | 0.84 | ZDHHC7 (0.46) | ZDHHC7SMN1; SMN2CA1CA2CA14 | |
| SCHEMBL1008732 | 0.84 | ZDHHC7 (0.50) | ZDHHC7SMN1; SMN2CA1CA2CA14 | |
| SCHEMBL5965786 | 0.83 | ZDHHC7 (0.65) | ZDHHC7SMN1; SMN2CA1CA2CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119661541-A | Synthesis method of 6- (tert-butoxycarbonyl) -3, 6-diazabicyclo [3.1.1] heptane | 上海馨远医药科技有限公司 | 2025-03-21 | — | — | CN | disclosed |
| US-11649244-B2 | Method for synthesizing diaza-bridged compound and a diaza-bridged compound | LinkChem Co., Ltd., Shanghai (CN) | 2023-05-16 | — | — | US | disclosed |
| CN-114516882-A | Preparation method of cycloalkane tetracarboxylic dianhydride | 烟台弘邦医药科技有限公司 | 2022-05-20 | — | — | CN | disclosed |
| EP-1795581-B1 | LUBRICATING OIL COMPOSITION CONTAINING ACRYLIC POLYMER | KURARAY CO (JP) | 2018-09-19 | — | — | EP | disclosed |
| WO-2014011863-A1 | METHOD OF TREATMENT WITH 3-CYCLOPROPYLCARBONYL-3,6-DIAZABICYCLO[3.1.1]HEPTANE | TARGACEPT, INC. (US) | 2014-01-16 | — | — | WO | disclosed |
| WO-2012125518-A1 | SALT FORMS OF 3 - CYCLOPROPYLCARBONYL - 3, 6 - DIAZABICYCLO [3.1.1] HEPTANE | TARGACEPT, INC. (US) | 2012-09-20 | — | — | WO | disclosed |
| EP-1714992-B1 | THERMOPLASTIC ELASTOMER COMPOSITION AND MOLDED ARTICLE | KANEKA CORP (JP) | 2011-03-16 | — | — | EP | disclosed |
| EP-1398353-B1 | THERMOPLASTIC RESIN COMPOSITION | KANEKA CORP (JP) | 2010-10-13 | — | — | EP | disclosed |
| US-7799869-B2 | Thermoplastic elastomer composition and molded article | KANEKA CORPORATION (JP) | 2010-09-21 | — | — | US | disclosed |
| US-7732529-B2 | Thermoplastic elastomer composition and molded article | KANEKA CORPORATION (JP) | 2010-06-08 | — | — | US | disclosed |
| EP-1398353-A1 | THERMOPLASTIC RESIN COMPOSITION | Kaneka Corporation (JP) | 2004-03-17 | — | — | EP | disclosed |
| EP-0607374-B1 | NOVEL CYCLIC LIPID DERIVATIVES AS POTENT PAF ANTAGONISTS | PO HANG IRON & STEEL (KR) | 1999-04-07 | — | — | EP | disclosed |
| US-5700817-A | Cyclic lipid derivatives as potent PAF antagonists | POHANG IRON & STEEL CO., LTD. (KR) | 1997-12-23 | — | — | US | disclosed |
| US-5610310-A | Cyclic lipid derivatives as potent PAF antagonists | POHANG IRON & STEEL CO., LTD (KR) | 1997-03-11 | — | — | US | disclosed |
| EP-0299513-B1 | Azetidine derivatives, compositions and their use | FIDIA GEORGETOWN INST (US) | 1994-10-05 | — | — | EP | disclosed |
| EP-0607374-A1 | NOVEL CYCLIC LIPID DERIVATIVES AS POTENT PAF ANTAGONISTS | POHANG IRON & STEEL CO., LTD. (KR) | 1994-07-27 | — | — | EP | disclosed |
| WO-1994000447-A1 | NOVEL CYCLIC LIPID DERIVATIVES AS POTENT PAF ANTAGONISTS | POHANG IRON & STEEL CO., LTD. (KR) | 1994-01-06 | — | — | WO | disclosed |
| US-4990504-A | Modulate excitatory amino acid receptor system | FIDIA-GEORGETOWN INSTITUTE FOR THE NEUROSCIENCES (US) | 1991-02-05 | — | — | US | disclosed |
| US-4946839-A | ALZHEIMER'S DISEASE | FIDIA-GEORGETOWN INSTITUTE FOR THE NEUROSCIENCES (US) | 1990-08-07 | — | — | US | disclosed |
| EP-0299513-A1 | Azetidine derivatives, compositions and their use | FIDIA-GEORGETOWN INSTITUTE FOR THE NEUROSCIENCES (US) | 1989-01-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11649244-B2 | Method for synthesizing diaza-bridged compound and a diaza-bridged compound | DGAT2, NOS2, ABL1 | ZDHHC7 801/4885SMN1; SMN2 1887/4885CA1 2270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.